Chat with us, powered by LiveChat
Toggle Mobile Navigation

Robert A Paarlberg

Robert Paarlberg is the Principal of Paarlberg & Associates LLC, a consultancy founded in 2010 which specializes in US and EU clinical trial disclosure strategy and operations as well as regulatory policy and intelligence. Bob has more than 35 years of pharmaceutical industry experience with the vast majority of his experience in US and international regulatory affairs.

Prior to founding Paarlberg & Associates LLC, Bob created and directed global regulatory policy and intelligence functions at UCB and Pharmacia (Upjohn). Bob has been actively involved with clinical trial disclosure since 2005 when he was responsible for implementing UCB’s clinical trial disclosure processes. He also established Upjohn’s FDA liaison office in Washington, DC and worked closely with the Government Affairs team on key federal legislative issues.

Bob is the former Chair of DIA’s Clinical Trial Disclosure Community (2013 – 2018). He is also a founding member of the Washington Regulatory Liaison Group.

Bob is a member of Alliance for a Stronger FDA, DIA’s Clinical Trial Disclosure Community, RAPS, and an Advisory Board member of RegLink Associates. Bob is a frequent speaker at conferences on clinical trial disclosure and transparency. He received a M.S. in Analytical Chemistry from Purdue University.

Bob has co-authored two papers in the Drug Information Journal: “FDAAA Basic Results Reporting: First Experience and Challenges” (May 2011) and “Outcome Measures in Study Registries: The Need for a Consistent Approach” (April 2012).

Robert A has spoken at the following ExL Events:

live chat software